These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7688738)

  • 1. Deletion of the SH3 domain of Src interferes with regulation by the phosphorylated carboxyl-terminal tyrosine.
    Okada M; Howell BW; Broome MA; Cooper JA
    J Biol Chem; 1993 Aug; 268(24):18070-5. PubMed ID: 7688738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae.
    Murphy SM; Bergman M; Morgan DO
    Mol Cell Biol; 1993 Sep; 13(9):5290-300. PubMed ID: 7689149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the binding of the Src homology 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src.
    Sabe H; Hata A; Okada M; Nakagawa H; Hanafusa H
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3984-8. PubMed ID: 7513429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nonreceptor protein-tyrosine kinase CSK complexes directly with the GTPase-activating protein-associated p62 protein in cells expressing v-Src or activated c-Src.
    Neet K; Hunter T
    Mol Cell Biol; 1995 Sep; 15(9):4908-20. PubMed ID: 7544435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains.
    Weng Z; Thomas SM; Rickles RJ; Taylor JA; Brauer AW; Seidel-Dugan C; Michael WM; Dreyfuss G; Brugge JS
    Mol Cell Biol; 1994 Jul; 14(7):4509-21. PubMed ID: 7516469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Csk suppression of Src involves movement of Csk to sites of Src activity.
    Howell BW; Cooper JA
    Mol Cell Biol; 1994 Aug; 14(8):5402-11. PubMed ID: 7518562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src.
    Hirai H; Varmus HE
    Mol Cell Biol; 1990 Apr; 10(4):1307-18. PubMed ID: 2108315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src.
    Seidel-Dugan C; Meyer BE; Thomas SM; Brugge JS
    Mol Cell Biol; 1992 Apr; 12(4):1835-45. PubMed ID: 1549129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713).
    Hjermstad SJ; Peters KL; Briggs SD; Glazer RI; Smithgall TE
    Oncogene; 1993 Aug; 8(8):2283-92. PubMed ID: 7687763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms.
    Bjorge JD; Bellagamba C; Cheng HC; Tanaka A; Wang JH; Fujita DJ
    J Biol Chem; 1995 Oct; 270(41):24222-8. PubMed ID: 7592628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.
    Mayer BJ; Baltimore D
    Mol Cell Biol; 1994 May; 14(5):2883-94. PubMed ID: 8164650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p80/85 cortactin associates with the Src SH2 domain and colocalizes with v-Src in transformed cells.
    Okamura H; Resh MD
    J Biol Chem; 1995 Nov; 270(44):26613-8. PubMed ID: 7592885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the cellular src protein tyrosine kinase: interactions of the carboxyl terminal sequences residing between the kinase domain and tyrosine-527.
    Cobb BS; Parsons JT
    Oncogene; 1993 Nov; 8(11):2897-903. PubMed ID: 7692368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src.
    Superti-Furga G; Fumagalli S; Koegl M; Courtneidge SA; Draetta G
    EMBO J; 1993 Jul; 12(7):2625-34. PubMed ID: 7687537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.
    Erpel T; Superti-Furga G; Courtneidge SA
    EMBO J; 1995 Mar; 14(5):963-75. PubMed ID: 7534229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine-phosphorylated epidermal growth factor receptor and cellular p130 provide high affinity binding substrates to analyze Crk-phosphotyrosine-dependent interactions in vitro.
    Birge RB; Fajardo JE; Mayer BJ; Hanafusa H
    J Biol Chem; 1992 May; 267(15):10588-95. PubMed ID: 1375224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
    Tian M; Martin GS
    Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Domain interactions in protein tyrosine kinase Csk.
    Sondhi D; Cole PA
    Biochemistry; 1999 Aug; 38(34):11147-55. PubMed ID: 10460171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective binding of activated pp60c-src by an immobilized synthetic phosphopeptide modeled on the carboxyl terminus of pp60c-src.
    Roussel RR; Brodeur SR; Shalloway D; Laudano AP
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10696-700. PubMed ID: 1720546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphopeptide occupancy and photoaffinity cross-linking of the v-Src SH2 domain attenuates tyrosine kinase activity.
    Garcia P; Shoelson SE; Drew JS; Miller WT
    J Biol Chem; 1994 Dec; 269(48):30574-9. PubMed ID: 7527032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.